What is the recommended treatment for peripheral arterial disease?

Treatment for Peripheral Arterial Disease

All patients with symptomatic peripheral arterial disease should receive aspirin 75-325 mg daily or clopidogrel 75 mg daily as antiplatelet therapy, high-intensity statin therapy regardless of baseline lipids, smoking cessation with pharmacotherapy, and supervised exercise training for at least 12 weeks before considering revascularization. 1, 2

Cardiovascular Risk Reduction (Mandatory for All Symptomatic PAD)

Antiplatelet Therapy

• Aspirin 75-325 mg daily is first-line antiplatelet therapy to reduce myocardial infarction, stroke, and vascular death in all symptomatic PAD patients, including those with intermittent claudication, critical limb ischemia, or prior revascularization. 1

• Clopidogrel 75 mg daily is an equally effective and safe alternative to aspirin for reducing MI, ischemic stroke, and vascular death. 1

• Dual pathway inhibition with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily should be considered in high-risk patients (especially post-revascularization) who have low bleeding risk to further reduce cardiovascular and limb events. 2

• Dual antiplatelet therapy (aspirin plus clopidogrel) may be considered in high-risk symptomatic PAD patients not at increased bleeding risk, though cardiovascular benefit remains uncertain. 1

• Warfarin should NOT be added to antiplatelet therapy—it provides no cardiovascular benefit and significantly increases major bleeding risk. 1

Lipid Management

• High-intensity statin therapy is mandatory for every PAD patient regardless of baseline LDL-cholesterol levels to reduce cardiovascular events. 1, 2

• Target LDL-cholesterol should be <1.4 mmol/L (55 mg/dL) for PAD patients at very high cardiovascular risk. 1

• For statin-intolerant patients not achieving LDL goals on ezetimibe, add bempedoic acid alone or combined with a PCSK9 inhibitor. 1

Blood Pressure Management

• Antihypertensive treatment reduces MI, stroke, heart failure, and cardiovascular death in PAD patients. 2

• ACE inhibitors or ARBs are preferred antihypertensives because they provide additional reduction in ischemic events beyond blood pressure control. 2

Diabetes Management

• Tight glycemic control (HbA1c <53 mmol/mol or <7%) reduces microvascular complications in PAD patients with diabetes. 1

• SGLT2 inhibitors with proven cardiovascular benefit should be used in type 2 diabetes patients with PAD to reduce cardiovascular events, independent of baseline HbA1c. 1

• GLP-1 receptor agonists with proven cardiovascular benefit are also recommended for type 2 diabetes patients with PAD to reduce cardiovascular events. 1

Smoking Cessation

• Ask about tobacco use status at every visit for all current or former smokers. 1

• Provide behavioral counseling and develop a specific quit plan at each encounter. 1

• Offer pharmacologic smoking-cessation aids: varenicline, bupropion, or nicotine replacement therapy in the absence of contraindications. 1, 2

Symptom Management for Intermittent Claudication

Exercise Therapy (First-Line Treatment)

• Supervised exercise training is the initial therapy and must be completed before considering any revascularization for claudication. 1, 2

• Program specifications: 30-45 minutes per session, at least 3 sessions per week, continued for a minimum of 12 weeks. 1, 2

• Exercise should be treadmill or track walking to near-maximal pain, followed by rest, then resumed—this cycle repeated throughout each session. 1, 2

• Supervised programs are superior to unsupervised home programs; structured home-based programs with behavioral change techniques are acceptable only when supervised programs are unavailable. 2

• Unstructured advice to "just walk more" does NOT improve outcomes and should be avoided. 2

Pharmacologic Therapy for Claudication

• Cilostazol 100 mg twice daily improves symptoms and walking distance and should be prescribed to all patients with lifestyle-limiting claudication who do not have heart failure. 1, 2

• Pentoxifylline 400 mg three times daily may be used as a second-line option, but its clinical benefit is marginal and not well established. 2

• L-arginine, propionyl-L-carnitine, and ginkgo biloba have no proven effectiveness for claudication and should NOT be used. 2

• Chelation therapy with EDTA is contraindicated due to potential harm. 2

Revascularization: Indications and Approach

When to Revascularize

• Revascularization is indicated only when claudication remains disabling after inadequate response to at least 3 months of supervised exercise and optimal medical therapy. 1, 2

• The patient must have significant disability—unable to perform normal work or serious impairment of activities important to them. 1

• Lesion anatomy must suggest low procedural risk with high probability of initial and long-term success. 1

• Revascularization is NOT indicated for asymptomatic PAD or solely to prevent progression to critical limb-threatening ischemia. 1, 2

Aortoiliac Disease

• Endovascular therapy is preferred for TASC A and B iliac lesions. 2

• Primary stenting is effective for common and external iliac artery stenoses/occlusions; use provisional stenting when balloon angioplasty leaves residual gradient >10 mmHg, >50% stenosis, or flow-limiting dissection. 2

Femoropopliteal Disease

• Endovascular therapy is preferred for TASC A femoropopliteal lesions. 2

• Drug-eluting technologies (drug-eluting balloons or stents) are first-choice for femoropopliteal lesions. 1, 2

• Primary stenting is NOT recommended in femoral, popliteal, or tibial arteries—reserve stenting for salvage after failed balloon angioplasty. 2

• When autologous great saphenous vein is available and surgical risk is low, open bypass using vein is preferred for extensive femoropopliteal disease (TASC C/D lesions). 2

Post-Revascularization Management

• Continue supervised exercise training as adjunct therapy after endovascular revascularization. 2

• Consider adding rivaroxaban 2.5 mg twice daily plus aspirin post-revascularization to further reduce cardiovascular and limb events. 2

Critical Limb-Threatening Ischemia (CLTI)

• Early recognition of CLTI (ischemic rest pain, non-healing wounds, gangrene) and immediate referral to a vascular specialist team are mandatory for limb salvage. 1, 2

• Revascularization is recommended for limb salvage in all CLTI patients whenever anatomically feasible. 1, 2

• Expedited evaluation and treatment of factors increasing amputation risk (infection, inadequate offloading, uncontrolled diabetes) must occur immediately. 1

• Systemic antibiotics should be initiated promptly in CLTI patients with skin ulcerations and evidence of limb infection. 1

• Patients with CLTI require at least twice-yearly follow-up by a vascular specialist due to high recurrence rates. 1

Follow-Up and Surveillance

• All PAD patients should be followed at least annually, assessing clinical and functional status, medication adherence, limb symptoms, cardiovascular risk factors, with duplex ultrasound as needed. 1

• After successful CLTI treatment, feet should be examined directly (shoes and socks removed) at regular intervals to detect recurrence. 1

Common Pitfalls to Avoid

• Do NOT proceed to revascularization without first completing at least 3 months of supervised exercise and optimal medical therapy for claudication—this violates guideline recommendations. 1, 2

• Do NOT use primary stenting in femoral, popliteal, or tibial arteries except as salvage strategy after failed angioplasty. 2

• Do NOT add warfarin to antiplatelet regimens unless another indication exists (e.g., atrial fibrillation)—it increases bleeding without cardiovascular benefit. 1

• Do NOT recommend unstructured "just walk more" programs—they are ineffective and waste valuable treatment time. 2

• Do NOT withhold cilostazol in eligible claudication patients without heart failure—it has Level A evidence for symptom improvement. 1, 2

• Do NOT treat asymptomatic PAD with revascularization—there is no benefit and potential harm. 1, 2